UroAlert - GU Oncology Weekly

August 21, 2025

Videos

Peer-to-Peer Clinical Conversations

Technology-Driven Innovation in Bladder Cancer: Surgery, Surveillance, and Beyond – Saum Ghodoussipour

Saum Ghodoussipour

Ashish Kamat hosts Saum Ghodoussipour to discuss a tech-driven bladder cancer breakout session at the BCAN Think Tank.

Optimal ARPI Selection in Metastatic Hormone-Sensitive Prostate Cancer: A Case Study - Pedro Barata

Pedro Barata

Neeraj Agarwal is joined by Pedro Barata to discuss metastatic hormone-sensitive prostate cancer through a compelling case study and recent advances.

Beyond the Abstracts

Avelumab-Based Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (AURA Oncodistinct-004): A Phase 2 Multicenter Clinical Trial - Beyond the Abstract

Active Surveillance Selection and 3-Year Durability in Intermediate-Risk Prostate Cancer Following Genomic Testing - Beyond the Abstract

Conference Coverage

BCANTT 2025: Overcoming Immune Suppressive Myeloid Cell Barriers in Bladder Cancer

BCANTT 2025: Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies

BCANTT 2025: Alliance A031501: AMBASSADOR Study. Managing a Cooperative Group Study in a Rapidly Evolving Treatment Landscape

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin and Pembrolizumab: A Path to Cure?

VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee.

Silent but Invasive: A Case Report of a Sarcomatoid Bladder Carcinoma in a 29-Year-Old Male Presenting As Vesico-Cutaneous Fistula Without Hematuria.

Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study.

Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment.

Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence.

FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ.

Hyperthermic intravesical chemotherapy for Bacillus Calmette-Guérin-unresponsive nonmuscle-invasive bladder cancer.

Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast.

Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer.

Partial Cystectomy for Muscle-Invasive Bladder Cancer.

Avelumab-Based Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (AURA Oncodistinct-004): A Phase 2 Multicenter Clinical Trial - Beyond the Abstract

Trimodal Treatment vs Radical Cystectomy for Muscle-invasive Bladder Cancer: the Neglected Impact of Informative Censoring. A Systematic Review and Meta-analysis - Beyond the Abstract

Penile & Urethral Cancers

International Society of Urological Pathology (ISUP) Multidisciplinary Consensus on Premalignant and Putative Precursor Lesions of Penile Cancer: Working Group 5 report on Terminology, Grading, and Molecular Testing Practices.

Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer.

Prior Radiation Therapy is Associated with Increased Risk of Intraoperative Complications in Patients Undergoing Primary Inflatable Penile Prosthesis Placement: Results from a Large Multi-Institutional Collaborative.

Renal Cancer

Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma.

Exploring Management Preferences Among Patients with Small Renal Masses: Results from a Pilot Study.

Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study.

Protein modifications by advanced glycation end products (AGEs) in human clear cell renal cell carcinoma.

Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α).

Personalized survival predictions in chromophobe renal cell carcinoma: development of a machine learning-based web tool.

BCL-xL dependency in chromophobe renal cell carcinoma.

Comparison of coaxial technique with sequential (non-coaxial) technique for renal mass biopsy: evaluation of diagnostic efficacy, complication rates, seeding risk, and clinical outcomes.

CD70-targeted allogeneic CAR T-Cell therapy for clear cell renal cell carcinoma.

Biomarkers in Renal Cell Carcinoma: A Systematic Review and Immunohistochemical Validation Study.

Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma.

Radiogenomic Correlation of Hypoxia-Related Biomarkers in Clear Cell Renal Cell Carcinoma - Beyond the Abstract

Clonal Hematopoiesis in Metastatic Urothelial and Renal Cell Carcinoma - Beyond the Abstract

Biologically Targeted Dual Adaptive and Innate Nano-Immunotherapy for Clear Cell Renal Cell Carcinoma Treatment - Beyond the Abstract

Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma - Beyond the Abstract

Prostate Cancer

A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer.

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.

Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate-Resistant Prostate Cancer (CRPC) Patients: CaPA Study.

Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients.

Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional Collaboration.

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts.

The Effect of Preoperative Magnetic Resonance Imaging on Long-term Oncological Outcomes Following Radical Prostatectomy-A 12-year Follow-up of a Randomized Controlled Trial.

Prostate Volume and PSA-Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics.

Learning curve of a multidisciplinary team for magnetic resonance imaging/transperineal ultrasonography fusion prostate biopsy.

Long-term urinary complications in patients with localized prostate cancer treated with radiotherapy and/or radical prostatectomy.

Prognostic Stratification of pN1 Prostate Cancer After Radical Prostatectomy: A Competing Risk Analysis from a Multi-institutional Cohort.

Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration Resistant Prostate Cancer.

Bowel bag dosimetric parameters for ultrahypofractionated pelvic elective nodal irradiation in prostate cancer.

Options in nuclear medicine for advanced prostate cancer in practice.

Disparities in MRI and TRUS for prostate cancer detection: A systematic review and meta-analysis of 94,020 cases.

Magnetic resonance guided stereotactic reirradiation for locally recurrent prostate cancers: Long-term results from a prospective registry study.

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.

Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.

Improving Clinically Significant Prostate Cancer Detection with a Multimodal Machine Learning Approach: A Large-Scale Multicenter Study.

Active surveillance for low-risk prostate cancer: long-term utilization and outcomes among black men.

Early nutritional and inflammation assessment predicts prognosis in patients with cancer across tumor origin and metastaticc status.

Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the US Medicare Fee-For-Service Population.

Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.

Radiation Chronotherapy in Prostate Cancer: Does Time of Day of Radiation Treatment Influence Disease Outcome or Symptom Burden?

A multimodal automated deep learning-based model for predicting biochemical recurrence of prostate cancer following prostatectomy from baseline MRI, Presurgical clinical covariates.

Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer.

Adverse Pathology After Radical Prostatectomy in Low- and Intermediate-Risk Prostate Cancer: A Propensity Score-Matched Analysis of Long-Term Health-Related Quality of Life.

Furosemide Reduces Radionuclide Activity in the Bladder in 18F-PSMA-1007-PET/CT: A Single-Center Retrospective Intra-Individual Comparative Study.

Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Case Series Exploring Hormonal Sensitivity in Prostate Cancer Patients Harboring the Germline African-Ancestry HOXB13 X285K Variant - Beyond the Abstract

Combined Hypofractionated Radiation Therapy and Brachytherapy for Managing Prostate-Specific Membrane Antigen Positron Emission Tomography-Staged Organ-Confined Prostate Cancer: Primary Endpoint Analysis of a Prospective Study - Beyond the Abstract

Upper Tract Tumors

Comparative efficacy of kidney-sparing surgery versus radical nephroureterectomy for high-risk middle-lower ureteral urothelial carcinoma: a retrospective analysis.

Lymphadenectomy in upper tract urothelial carcinoma: Clinical insights and controversies (Review).

Challenges in Follow-up After Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Insights from a Delphi Consensus.

Diagnosis and Management of Upper Tract Urothelial Carcinoma: A Review.

Oncologic and Renal Function Outcomes of Segmental Ureterectomy vs. Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis - Beyond the Abstract

Testicular Cancer

Analysis of the Increased Incidence of Aggressive Prostate Cancer After Prior Testicular Cancer.

Pathologic and Oncologic Outcomes of Patients Undergoing Orchiectomy After Chemotherapy for Advanced Testicular Germ Cell Tumors.

Postnatal determinants of testicular germ cell tumor by histological subtypes: The EPSAM1 and EPSAM2 studies.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC